Skip to content
Disclosery

Rosalind Advisors, Inc.

Follow

13F filer, CIK 1622627, TORONTO, Ontario, Canada

Rosalind Advisors, Inc. reported $269,201,776 across 35 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 74.86% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001622627-26-000022

Period
2026-06-30
Reported value
$269M
Holdings
35
Top 10 weight
74.86%
New
9
Sold out
12

Largest buys vs the previous quarter

SecurityShares changeApprox. value
VSTMadded+1,848,034$7.06M
FENCadded+279,800$3.01M
HELPadded+425,000$2.81M
ABVXnew+20,869$2.78M
TLPHadded+1,815,585$1.87M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CGONexited-100,000-$6.77M
PCVXreduced-90,000-$5.23M
VRDNexited-250,401-$4.9M
CLDXreduced-130,000-$4.84M
XERSreduced-322,719-$2.56M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001622627-26-000022, largest first. % of portfolio is the value over $266,234,296, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
DCTHDELCATH SYS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,650,389 shares; 2024Q4: 2,650,389 shares; 2025Q1: 2,900,389 shares; 2025Q2: 3,300,389 shares; 2025Q3: 3,300,389 shares; 2025Q4: 3,300,389 shares; 2026Q1: 3,300,389 shares; 2026Q2: 3,300,389 shares 3,300,389$41.6M15.61%02026-10-13, Form 4: converted 3,627 shares on 2026-10-13 Timeline
FENCFENNEC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 1,259,876 shares; 2025Q1: 1,782,844 shares; 2025Q2: 2,045,644 shares; 2025Q3: 2,076,840 shares; 2025Q4: 2,613,508 shares; 2026Q1: 2,908,201 shares; 2026Q2: 3,188,001 shares 3,188,001$34.3M12.87%+279,800Timeline
XERSXERIS BIOPHARMA HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,104,995 shares; 2024Q4: 3,104,995 shares; 2025Q1: 2,495,986 shares; 2025Q2: 2,155,594 shares; 2025Q3: 1,795,766 shares; 2025Q4: 2,111,700 shares; 2026Q1: 3,231,700 shares; 2026Q2: 2,908,981 shares 2,908,981$23M8.65%-322,719Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 2,654,944 shares; 2025Q1: 2,654,944 shares; 2025Q2: 2,654,944 shares; 2025Q3: 4,000,000 shares; 2025Q4: 3,403,721 shares; 2026Q1: 3,203,721 shares; 2026Q2: 3,178,121 shares 3,178,121$19.6M7.35%-25,600Timeline
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 900,000 shares; 2025Q1: 2,644,517 shares; 2025Q2: 2,043,563 shares; 2025Q3: 1,929,563 shares; 2025Q4: 1,788,475 shares; 2026Q1: 2,138,475 shares; 2026Q2: 3,986,509 shares 3,986,509$15.2M5.72%+1,848,034Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,544,607 shares; 2025Q4: 2,605,920 shares; 2026Q1: 3,214,766 shares; 2026Q2: 3,214,766 shares 3,214,766$15M5.64%0Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 650,000 shares; 2025Q4: 690,000 shares; 2026Q1: 1,036,737 shares; 2026Q2: 988,230 shares 988,230$14.1M5.31%-48,507Timeline
HELPCYBIN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 810,918 shares; 2025Q1: 810,918 shares; 2025Q2: 810,918 shares; 2025Q3: 1,500,000 shares; 2025Q4: 1,657,540 shares; 2026Q1: 1,531,814 shares; 2026Q2: 1,956,814 shares 1,956,814$12.9M4.86%+425,000Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 700,000 shares; 2026Q2: 648,600 shares 648,600$11.9M4.49%-51,400Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 290,000 shares; 2026Q2: 200,000 shares 200,000$11.6M4.37%-90,000Timeline
MDWDMEDIWOUND LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 628,050 shares; 2024Q4: 628,050 shares; 2025Q1: 506,893 shares; 2025Q2: 407,061 shares; 2025Q3: 749,054 shares; 2025Q4: 749,054 shares; 2026Q1: 749,054 shares; 2026Q2: 749,054 shares 749,054$11M4.14%0Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 330,000 shares; 2026Q2: 200,000 shares 200,000$7.44M2.8%-130,000Timeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 923,057 shares; 2026Q2: 721,504 shares 721,504$7.22M2.71%-201,553Timeline
PROFPROFOUND MED CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 485,973 shares; 2024Q4: 692,185 shares; 2025Q1: 692,185 shares; 2025Q2: 692,185 shares; 2025Q3: 692,185 shares; 2025Q4: 1,068,955 shares; 2026Q1: 828,118 shares; 2026Q2: 828,118 shares 828,118$5.51M2.07%0Timeline
TLPHTALPHERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 758,966 shares; 2024Q4: 613,939 shares; 2025Q1: 2,003,939 shares; 2025Q2: 2,003,939 shares; 2025Q3: 4,385,757 shares; 2025Q4: 3,579,273 shares; 2026Q1: 3,353,916 shares; 2026Q2: 5,169,501 shares 5,169,501$5.32M2%+1,815,585Timeline
AVIRATEA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,171,855 shares; 2026Q2: 1,070,550 shares 1,070,550$4.98M1.87%-101,305Timeline
MYOMYOMO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,021,391 shares; 2024Q4: 2,998,945 shares; 2025Q1: 2,703,661 shares; 2025Q2: 3,595,788 shares; 2025Q3: 3,790,788 shares; 2025Q4: 3,839,772 shares; 2026Q1: 3,847,272 shares; 2026Q2: 3,637,886 shares 3,637,886$3.78M1.42%-209,386Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 500,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,107,994 shares; 2026Q2: 1,107,994 shares 1,107,994$2.98M1.12%0Timeline
NRXSNEURAXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 286,138 shares; 2026Q1: 286,138 shares; 2026Q2: 508,055 shares 508,055$2.97M1.12%+221,917Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 139,983 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 20,869 shares 20,869$2.78M1.04%newTimeline
NSPRINSPIREMD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,514,046 shares; 2024Q4: 2,495,783 shares; 2025Q1: 2,274,990 shares; 2025Q2: 2,289,099 shares; 2025Q3: 3,905,743 shares; 2025Q4: 3,905,743 shares; 2026Q1: 3,905,743 shares; 2026Q2: 3,905,743 shares 3,905,743$2.73M1.03%0Timeline
RGNTREGENTIS BIOMATERIALS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 251,510 shares; 2026Q1: 251,510 shares; 2026Q2: 701,685 shares 701,685$2.48M0.93%+450,175Timeline
PYPDPOLYPID LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 679,168 shares; 2024Q4: 1,018,021 shares; 2025Q1: 1,018,021 shares; 2025Q2: 975,462 shares; 2025Q3: 918,668 shares; 2025Q4: 696,556 shares; 2026Q1: 597,926 shares; 2026Q2: 389,455 shares 389,455$1.98M0.74%-208,471Timeline
BFRIBIOFRONTERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 495,490 shares; 2024Q4: 811,918 shares; 2025Q1: 644,393 shares; 2025Q2: 976,448 shares; 2025Q3: 1,140,764 shares; 2025Q4: 1,140,764 shares; 2026Q1: 1,163,962 shares; 2026Q2: 1,275,609 shares 1,275,609$1.21M0.45%+111,647Timeline
KURAKURA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 100,000 shares; 2025Q2: 100,000 shares; 2025Q3: 100,000 shares; 2025Q4: 100,000 shares; 2026Q1: 100,000 shares; 2026Q2: 100,000 shares 100,000$1.1M0.41%0Timeline
SPRBSPRUCE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 20,000 shares 20,000$1.08M0.41%newTimeline
AQSTAQUESTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 250,000 shares; 2026Q2: 250,000 shares 250,000$1.04M0.39%0Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 730,488 shares; 2026Q1: 443,763 shares; 2026Q2: 150,000 shares 150,000$684K0.26%-293,763Timeline
PEPGPEPGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 350,000 shares 350,000$630K0.24%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
SELLAS LIFE SCIENCES GROUP ISELLAS LIFE SCIENCES GROUP I PUTput568,700$2.3Mnew
CG ONCOLOGY INCCG ONCOLOGY INC CALLcall31,000$375Knew
EYEPOINT INCEYEPOINT INC CALLcall50,300$131Knew
ISHARES TRISHARES TR PUTput500,000$110Knew
SPDR SERIES TRUSTSPDR SERIES TRUST PUTput140,600$35.1Knew
TENAX THERAPEUTICS INCTENAX THERAPEUTICS INC PUTput6,200$13.9Knew

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CGONCG ONCOLOGY INC100,000$6.77Mshares
VRDNVIRIDIAN THERAPEUTICS INC250,401$4.9Mshares
REPLIMUNE GROUP INCREPLIMUNE GROUP INC1,275,600$2.75Mcall
DFTXDEFINIUM THERAPEUTICS INC125,000$2.36Mshares
LPCNLIPOCINE INC NEW221,616$1.77Mshares
AVTXAVALO THERAPEUTICS INC75,000$1.12Mshares
ANNXANNEXON INC200,000$1.11Mshares
INVESCO QQQ TRINVESCO QQQ TR250,000$1.05Mput
STATE STR SPDR S&P 500 ETF TSTATE STR SPDR S&P 500 ETF T125,000$958Kput
VIRIDIAN THERAPEUTICS INCVIRIDIAN THERAPEUTICS INC263,600$52.7Kput
UNIQURE NVUNIQURE NV295,800$0call
ARRIVENT BIOPHARMA INCARRIVENT BIOPHARMA INC108,900$0call

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001622627-26-000022 base2026-08-14acceptance time not in the bulk data set